Opdivo (nivolumab) Global Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

Description

Opdivo (nivolumab) is a prescription medication classified as an immune checkpoint inhibitor, specifically targeting programmed death-1 (PD-1) receptors. It is a form of immunotherapy used to treat various types of cancer by enhancing the body's immune system to recognize and eliminate cancer cells.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The primary formulations available in the opdivo (nivolumab) market include 40 mg/4 ml, 100 mg/10 ml, and 240 mg/24 ml. The 40 mg/4 ml dosage is a lower concentration, intended for patients who need smaller doses, typically used in specific treatment protocols or for patients with lower body weight. These formulations are available in various forms, including injections and solutions, and are used across different age groups, including both adults and pediatric patients. Opdivo is applied in the treatment of melanoma, non-small cell lung cancer (NSCLC), malignant pleural mesothelioma, classical Hodgkin lymphoma (CHL), squamous cell carcinoma of the head and neck (SCCHN), renal cell carcinoma (RCC), and other cancers. The primary end-users of Opdivo are hospitals, clinics, and other healthcare settings.

The opdivo (nivolumab) market research report is one of a series of new reports from The Business Research Company that provides opdivo (nivolumab) market statistics, including opdivo (nivolumab) industry global market size, regional shares, competitors with a opdivo (nivolumab) market share, detailed opdivo (nivolumab) market segments, market trends, and opportunities, and any further data you may need to thrive in the opdivo (nivolumab) industry. This opdivo (nivolumab) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The opdivo (nivolumab) market size is expected to see strong growth in the next few years. It will grow to $11,281.6 million in 2029 at a compound annual growth rate (CAGR) of 8%. The growth in the forecast period can be attributed to growing acceptance of immunotherapy, enhanced understanding of immunotherapy and its benefits, growth in healthcare expenditure for capital equipment, increasing the application of nivolumab for various indications, and growing preference for immunotherapy treatments. Major trends in the forecast period include product innovation, expansion into new geographic markets, ongoing clinical trials, growing trend towards personalized medicine, and advancements in cancer research.

The rising prevalence of non-small cell lung cancer (NSCLC) is anticipated to drive the growth of the opdivo (nivolumab) market in the coming years. NSCLC is the most prevalent form of lung cancer, representing approximately 85% of all lung cancer cases. The growing incidence of NSCLC can mainly be attributed to factors such as smoking, exposure to environmental pollutants, genetic mutations, and a family history of cancer. Opdivo functions by blocking the PD-1 receptor on immune cells, boosting the body's immune response to identify and attack cancer cells. For instance, in 2024, the American Cancer Society, a U.S.-based health organization, reported 234,580 new lung cancer cases diagnosed in the U.S., with 80% of those being NSCLC, showing an increase compared to 2023, when 238,340 people were diagnosed with lung cancer. Therefore, the rising incidence of non-small lung cancer is fueling the expansion of the opdivo (nivolumab) market.

A significant trend in the opdivo (nivolumab) market is the development of combination therapies to enhance treatment efficacy and broaden its use across various cancer types. These combination strategies aim to address resistance mechanisms and offer more comprehensive treatment alternatives for advanced cancer patients. For example, in October 2024, the U.S.-based Food and Drug Administration approved Opdivo (nivolumab) in combination with platinum-doublet chemotherapy as neoadjuvant treatment, followed by single-agent nivolumab post-surgery as adjuvant treatment for adults with resectable NSCLC. This approval allows Opdivo to be used in conjunction with platinum-doublet chemotherapy before surgery and as monotherapy afterward for patients without known EGFR or ALK mutations.

In November 2022, Lyvgen Biopharma, a biotech firm based in China, entered into a partnership with Bristol Myers Squibb (BMS). This collaboration aims to conduct a Phase II clinical trial assessing LVGN7409 in combination with Opdivo (nivolumab) for patients with advanced or metastatic NSCLC. Bristol Myers Squibb is the pharmaceutical company responsible for developing Opdivo (nivolumab).

Major players operating in the opdivo (nivolumab) market are Bristol-Myers Squibb, Ono Pharmaceutical.

North America was the largest region in the 0pdivo (nivolumab) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in opdivo (nivolumab) report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the opdivo (nivolumab) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The opdivo (nivolumab) market consists of sales of monotherapy and combination therapy. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Opdivo (nivolumab) Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on opdivo (nivolumab) market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 10 geographies.
Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 3-4 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for opdivo (nivolumab) ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The opdivo (nivolumab) market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:1) By Type: 40 mg/4 mL; 100 mg/10 mL; 240 mg/24 mL
2) By Dosage: Injection; Solution; Other Dosages
3) By Demographic: Adult; Pediatric
4) By Application: Melanoma; Non-small Cell Lung Cancer (NSCLC); Malignant Pleural Mesothelioma; Classical Hodgkin Lymphoma (CHL); Squamous Cell Carcinoma of the Head and Neck (SCCHN); Renal Cell Carcinoma (RCC); Other Applications
5) By End-User: Hospitals; Clinics; Other End Users
Companies Mentioned: Bristol-Myers Squibb; Ono Pharmaceutical
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.

Product Code: r33101

1. Executive Summary

2. Opdivo (Nivolumab) Market Characteristics

3. Opdivo (Nivolumab) Market Biologic Drug Characteristics

3.1. Molecule Type
3.2. Route Of Administration (ROA)
3.3. Mechanism Of Action (MOA)
3.4. Safety And Efficacy

4. Opdivo (Nivolumab) Market Trends And Strategies

5. Opdivo (Nivolumab) Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

6. Global Opdivo (Nivolumab) Growth Analysis And Strategic Analysis Framework

6.1. Global Opdivo (Nivolumab) PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
6.2. Analysis Of End Use Industries
6.3. Global Opdivo (Nivolumab) Market Growth Rate Analysis
6.4. Global Opdivo (Nivolumab) Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
6.5. Global Opdivo (Nivolumab) Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
6.6. Global Opdivo (Nivolumab) Total Addressable Market (TAM)

7. Global Opdivo (Nivolumab) Market Pricing Analysis & Forecasts

8. Opdivo (Nivolumab) Market Segmentation

8.1. Global Opdivo (Nivolumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
>40 mg/4 mL
100 mg/10 mL
240 mg/24 mL
8.2. Global Opdivo (Nivolumab) Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Injection
Solution
Other Dosages
8.3. Global Opdivo (Nivolumab) Market, Segmentation By Demographic, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Adult
Pediatric
8.4. Global Opdivo (Nivolumab) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Melanoma
Non-small Cell Lung Cancer (NSCLC)
Malignant Pleural Mesothelioma
Classical Hodgkin Lymphoma (CHL)
Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Renal Cell Carcinoma (RCC)
Other Applications
8.5. Global Opdivo (Nivolumab) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospitals
Clinics
Other End Users

9. Global Opdivo (Nivolumab) Market Epidemiology Of Clinical Indications

9.1. Drug Side Effects
9.2. Incidence And Prevalence of Clinical Indications

10. Opdivo (Nivolumab) Market Regional And Country Analysis

10.1. Global Opdivo (Nivolumab) Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. Global Opdivo (Nivolumab) Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Asia-Pacific Opdivo (Nivolumab) Market

11.1. Asia-Pacific Opdivo (Nivolumab) Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
11.2. Asia-Pacific Opdivo (Nivolumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Asia-Pacific Opdivo (Nivolumab) Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Asia-Pacific Opdivo (Nivolumab) Market, Segmentation By Demographic, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. China Opdivo (Nivolumab) Market

12.1. China Opdivo (Nivolumab) Market Overview
12.2. China Opdivo (Nivolumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
12.3. China Opdivo (Nivolumab) Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
12.4. China Opdivo (Nivolumab) Market, Segmentation By Demographic, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

13. India Opdivo (Nivolumab) Market

13.1. India Opdivo (Nivolumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. India Opdivo (Nivolumab) Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. India Opdivo (Nivolumab) Market, Segmentation By Demographic, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. Japan Opdivo (Nivolumab) Market

14.1. Japan Opdivo (Nivolumab) Market Overview
14.2. Japan Opdivo (Nivolumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. Japan Opdivo (Nivolumab) Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. Japan Opdivo (Nivolumab) Market, Segmentation By Demographic, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Australia Opdivo (Nivolumab) Market

15.1. Australia Opdivo (Nivolumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.2. Australia Opdivo (Nivolumab) Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Australia Opdivo (Nivolumab) Market, Segmentation By Demographic, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. South Korea Opdivo (Nivolumab) Market

16.1. South Korea Opdivo (Nivolumab) Market Overview
16.2. South Korea Opdivo (Nivolumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. South Korea Opdivo (Nivolumab) Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.4. South Korea Opdivo (Nivolumab) Market, Segmentation By Demographic, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Western Europe Opdivo (Nivolumab) Market

17.1. Western Europe Opdivo (Nivolumab) Market Overview
17.2. Western Europe Opdivo (Nivolumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Western Europe Opdivo (Nivolumab) Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.4. Western Europe Opdivo (Nivolumab) Market, Segmentation By Demographic, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. UK Opdivo (Nivolumab) Market

18.1. UK Opdivo (Nivolumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. UK Opdivo (Nivolumab) Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. UK Opdivo (Nivolumab) Market, Segmentation By Demographic, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Germany Opdivo (Nivolumab) Market

19.1. Germany Opdivo (Nivolumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Germany Opdivo (Nivolumab) Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Germany Opdivo (Nivolumab) Market, Segmentation By Demographic, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. France Opdivo (Nivolumab) Market

20.1. France Opdivo (Nivolumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. France Opdivo (Nivolumab) Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. France Opdivo (Nivolumab) Market, Segmentation By Demographic, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Opdivo (Nivolumab) Market

21.1. Eastern Europe Opdivo (Nivolumab) Market Overview
21.2. Eastern Europe Opdivo (Nivolumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Opdivo (Nivolumab) Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Opdivo (Nivolumab) Market, Segmentation By Demographic, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. North America Opdivo (Nivolumab) Market

22.1. North America Opdivo (Nivolumab) Market Overview
22.2. North America Opdivo (Nivolumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. North America Opdivo (Nivolumab) Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.4. North America Opdivo (Nivolumab) Market, Segmentation By Demographic, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. USA Opdivo (Nivolumab) Market

23.1. USA Opdivo (Nivolumab) Market Overview
23.2. USA Opdivo (Nivolumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. USA Opdivo (Nivolumab) Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. USA Opdivo (Nivolumab) Market, Segmentation By Demographic, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. Canada Opdivo (Nivolumab) Market

24.1. Canada Opdivo (Nivolumab) Market Overview
24.2. Canada Opdivo (Nivolumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. Canada Opdivo (Nivolumab) Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. Canada Opdivo (Nivolumab) Market, Segmentation By Demographic, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. South America Opdivo (Nivolumab) Market

25.1. South America Opdivo (Nivolumab) Market Overview
25.2. South America Opdivo (Nivolumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. South America Opdivo (Nivolumab) Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. South America Opdivo (Nivolumab) Market, Segmentation By Demographic, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. Middle East Opdivo (Nivolumab) Market

26.1. Middle East Opdivo (Nivolumab) Market Overview
26.2. Middle East Opdivo (Nivolumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. Middle East Opdivo (Nivolumab) Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. Middle East Opdivo (Nivolumab) Market, Segmentation By Demographic, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Africa Opdivo (Nivolumab) Market

27.1. Africa Opdivo (Nivolumab) Market Overview
27.2. Africa Opdivo (Nivolumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Africa Opdivo (Nivolumab) Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.4. Africa Opdivo (Nivolumab) Market, Segmentation By Demographic, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Opdivo (Nivolumab) Market Competitive Landscape And Company Profiles

28.1. Opdivo (Nivolumab) Market Competitive Landscape
28.2. Opdivo (Nivolumab) Market Company Profiles
- 28.2.1. Bristol-Myers Squibb Overview, Products and Services, Strategy and Financial Analysis
- 28.2.2. Ono Pharmaceutical Overview, Products and Services, Strategy and Financial Analysis

29. Global Opdivo (Nivolumab) Market Pipeline Analysis

29.1. High Level Clinic Trail Information

30. Global Opdivo (Nivolumab) Market Competitive Benchmarking And Dashboard

31. Key Mergers And Acquisitions In The Opdivo (Nivolumab) Market

32. Recent Developments In The Opdivo (Nivolumab) Market

33. Opdivo (Nivolumab) Market High Potential Countries, Segments and Strategies

33.1 Opdivo (Nivolumab) Market In 2029 - Countries Offering Most New Opportunities
33.2 Opdivo (Nivolumab) Market In 2029 - Segments Offering Most New Opportunities
33.3 Opdivo (Nivolumab) Market In 2029 - Growth Strategies
- 33.3.1 Market Trend Based Strategies
- 33.3.2 Competitor Strategies

34. Appendix

34.1. Abbreviations
34.2. Currencies
34.3. Historic And Forecast Inflation Rates
34.4. Research Inquiries
34.5. The Business Research Company
34.6. Copyright And Disclaimer